Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Martin Madaus
AddedMar 31, 2024
UpdatedJun 28, 2026
Martin Madaus

Martin Madaus

Board Member, Quanterix

CrunchbaseLinkedIn

Martin Madaus's Career

Quanterix
Quanterix

Billerica, MA, US

Board Member· Board
Standard BioTools
Standard BioTools

South San Francisco, CA, US

Board Member· Board
Repligen
Repligen

Waltham, MA, US

Board Member· Board
Ultivue
Ultivue

Cambridge, MA, US

Board Member· Board
Unchained Labs
Unchained Labs

Pleasanton, CA, US

Board Member· Board
Emulate
Emulate

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Martin Madaus's Career

Quanterix
Quanterix
Public$533.3M1252007Billerica, MA, US
Board Member· Board

Leadership at Quanterix

Nick NaclerioNick NaclerioBoard Member
Sarah HlavinkaSarah HlavinkaBoard Member
David WaltDavid WaltBoard Member
Masoud ToloueMasoud ToloueCEO
Kevin HrusovskyKevin HrusovskyBoard Member
Standard BioTools
Standard BioTools
Public$375.2M5231999South San Francisco, CA, US
Board Member· Board

Leadership at Standard BioTools

Fenel EloiFenel EloiBoard Member
Michael EgholmMichael EgholmCEO
Carlos PayaCarlos PayaBoard Member
Gajus WorthingtonGajus WorthingtonFounder
Gerhard F. Burbach, MBAGerhard F. Burbach, MBABoard Member
Repligen
Repligen
Public$1.3B2k1981Waltham, MA, US
Board Member· Board

Leadership at Repligen

Konstantin KonstantinovKonstantin KonstantinovBoard Member
Nicolas BarthelemyNicolas BarthelemyBoard Member
Glenn MuirGlenn MuirBoard Member
Rohin MhatreRohin MhatreBoard Member
Carrie Eglinton MannerCarrie Eglinton MannerBoard Member
Richard D. BraatzRichard D. BraatzBoard Member
Ultivue
Ultivue
Series D$107.3M562015Cambridge, MA, US
Board Member· Board

Leadership at Ultivue

Ralf JungmannRalf JungmannCo-Founder
Keith CrandellKeith CrandellBoard Member
Peng YinPeng YinCo-Founder
Adam WieschhausAdam WieschhausBoard Member
Rob CarsonRob CarsonCEO

Similar to Ultivue

Zinnia TechnologiesZinnia TechnologiesChicago, IL, USCare Toolsest. 2019Zinnia TechnologiesChicago, IL, US · est. 2019

Zinnia Technologies: A leading care tool provider, offering rewarding careers and a balanced work-life culture.

Pre-Seed · $120k6
ClearLight BiotechnologiesClearLight BiotechnologiesSunnyvale, CA, US3D Imaging, Tissue Analysisest. 2015ClearLight BiotechnologiesSunnyvale, CA, US · est. 2015

ClearLight Biotechnologies: Innovating non-destructive 3D tissue analysis for clinical research.

Seed · $12.3M11
Upstream BioUpstream BioWaltham, MA, USAntibody Therapyest. 2021Upstream BioWaltham, MA, US · est. 2021

Upstream Bio: Clinical-stage developer of monoclonal antibody therapy for severe asthma.

Series B · $408M17
Unchained Labs
Unchained Labs
Late Stage Private$285M2002015Pleasanton, CA, US
Board Member· Board

Leadership at Unchained Labs

Tim HarknessTim HarknessFounder & CEO
Laura HamillLaura HamillBoard Member
Heather PrestonHeather PrestonBoard Member
Joe KeeganJoe KeeganBoard Member
Emulate
Emulate
Series E$224.3M1192013Boston, MA, US
Board Member· Board

Leadership at Emulate

Jim CorbettJim CorbettBoard Member
Eric MoessingerEric MoessingerBoard Member
Sharon KedarSharon KedarBoard Member
Daniel LevnerDaniel LevnerBoard Member
Donald IngberDonald IngberBoard Member
Aaron VanDevenderAaron VanDevenderBoard Member

Similar to Emulate

eGenesiseGenesisCambridge, MA, USGene Editing, Organsest. 2015eGenesisCambridge, MA, US · est. 2015

eGenesis: Revolutionizing transplantation with a gene editing platform for human-compatible organs.

Series C · $265M105
Systemic BioSystemic BioHouston, TX, USOrgans-On-Chipsest. 2022Systemic BioHouston, TX, US · est. 2022

Systemic Bio leverages 3D technology to create bioprinted organs-on-chips for advanced drug discovery.

Seed · $15M11
BiomedInnovationsBiomedInnovationsDenver, NC, USMedical Devicesest. 2015BiomedInnovationsDenver, NC, US · est. 2015

BiomedInnovations: Pioneering tech for long-term storage and interaction with human tissues/organs.

Angel · $250k12
VivoSim LabsVivoSim LabsSan Diego, CA, USBioprinting, Medical Researchest. 2011VivoSim LabsSan Diego, CA, US · est. 2011

Innovative San Diego-based company specializing in 3D bioprinting for medical research and therapy.

Public · $112.3M39

Martin Madaus's Co-Investors

Stuart LevinsonStuart LevinsonCo-invested · Osmoses Pre-SeedAdrian PylypecAdrian PylypecCo-invested · Osmoses Pre-SeedAdrian PylypecAdrian PylypecCo-invested · Osmoses Pre-Seed

Martin Madaus's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Martin Madaus

Anthony ShuberAnthony ShuberFounder · Exact SciencesAndrew J. LastAndrew J. LastBoard Member · OncocyteSam ParlettSam ParlettCo-Founder · Shield BioTed OlsenTed OlsenCo-Founder · AquaLithLucy LuLucy LuBoard Member · Life Science AngelsBrent FawsonBrent FawsonBoard Member · Retrolux